Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 290, Issue 4, 2006, Pages

  Awad, Alaa S ^a   Huang, Liping ^a   Ye, Hong ^a   Duong, Elizabeth Thu Anh ^a   Bolton, W Kline ^a   Linden, Joel ^a,b   Okusa, Mark D ^a,b,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Atl146e; Diabetes; Kidney; Macrophage; Proteinuria

Indexed keywords

4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; ALBUMIN; CREATININE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; ADENOSINE A2 RECEPTOR; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; HISTOPATHOLOGY; INFLAMMATION; KIDNEY FUNCTION; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; URINE LEVEL; ALBUMINURIA; ANIMAL; DRUG POTENTIATION; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; KIDNEY; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALBUMINURIA; ANIMALS; CYCLOHEXANECARBOXYLIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; INFLAMMATION; KIDNEY; MICE; MICE, KNOCKOUT; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADENOSINE A2;

EID: 33645732363     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00310.2005     Document Type: Article

References (55)

1. American Diabetes Association. Position statement: diabetic nephropathy. Diabetes Care 24: S69-S72, 2001.
2. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, and Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58: 684-690, 2000.
3. Baud L, Oudinet JP, Bens M, Noe L, Peraldi MN, Rondeau F, Etienne J, and Ardaillou R. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35: 1111-1118, 1989.
4. Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, and Remuzzi G. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 65: 2193-2200, 2004.
5. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, and Remuzzi G. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 14: 1816-1824, 2003.
6. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, and Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44: 874-877, 2001.
7. Border WA and Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
8. Brands MW, Fitzgerald SM, Hewitt WH, and Hailman AE. Decreased cardiac output at the onset of diabetes: renal mechanisms and peripheral vasoconstriction. Am J Physiol Endocrinol Metab 278: E917-E924, 2000.
9. Brands MW and Hopkins TE. Poor glycemic control induced hypertension in diabetes mellitus. Hypertension 27: 753-759, 1996.
10. Bullough DA, Magill MJ, Firestein GS, and Mullane KM. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. J Immunol 155: 2579-2596, 1995.
11. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskwitz MA, Fink JS, and Schwarzschild MA. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19: 9192-9200, 1999.
12. Chen L, Hellmark T, Wieslander J, and Bolton WK. Immunodominant epitopes of α3(IV)NC1 induce autoimmune glomerulonephritis in rats. Kidney Int 64: 2108-2120, 2003.
13. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, and Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65: 116 -128, 2004.
14. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352: 213-219, 1998.
15. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, Schwarzschild MA, Fink JS, Linden J, and Okusa MD. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 112: 883-891, 2003.
16. Day YJ, Li Y, Rieger JM, Ramos SI, Okusa MD, and Linden J. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol 174: 5040-5046, 2005.
17. Dedhar S, Jewell K, Rojiani M, and Gray V. The receptor for the basement membrane glycoprotein entactin is the integrin α3/β1. J Biol Chem 267: 18908-18914, 1992.
18. Elices MJ, Urry LA, and Hemler ME. Receptor functions for the integrin VLA-3: fibronectin, collagen, and laminin binding are differentially influenced by Arg-Gly-Asp peptide and by divalent cations. J Cell Biol 112: 169-181, 1991.
19. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, and Yoshinaga K. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21: 480-485, 1993.
20. Gessi S, Varani K, Merighi S, Ongini E, and Borea PA. A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol 129: 2-11, 2000.
21. Gilbert RE and Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56: 1627-1637, 1999.
22. Hruby ZW and Lowry RP. Spontaneous release of tumor necrosis factor α by isolated renal glomeruli and cultured glomerular mesangial cells. Clin Immunol Immunopathol 59: 156-164, 1991.
23. Huang L, Wei YY, Momose-Hotokezaka A, Dickey J, and Okusa MD. α2B-adrenergic receptors: immunolocalization and regulation by potassium depletion in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 270: F1015-F1026, 1996.
24. Ikezumi Y, Atkins RC, and Nikolic-Paterson DJ. Interferon-γ augments acute macrophage-mediated renal injury via a glucocorticoid-sensitive mechanism. J Am Soc Nephrol 14: 888-898, 2003.
25. Kalantarinia K, Awad AS, and Siragy HM. Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64: 1208-1213, 2003.
26. Kelly DJ, Aaltonen P, Cox AJ, Rumble JR, Langham R, Panagiotopoulos S, Jerums G, Holthofer H, and Gilbert RE. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 17: 1327-1332, 2002.
27. Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC, and Bruijn JA. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 14: 2063-2071, 2003.
28. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41: 775-787, 2001.
29. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, and Gutierrez-Ramos JC. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 185: 1371-1380, 1997.
30. Ma G, Allen TJ, Cooper ME, and Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. Kidney Int 66: 1090-1098, 2004.
31. Meyer TW, Bennett PH, and Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 42: 1341-1344, 1999.
32. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10: 1778-1785, 1999.
33. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, and Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42: 450-456, 1993.
34. Nikolic-Paterson DJ and Atkins RC. The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16: 3-7, 2001.
35. Okusa MD, Huang L, Momose-Hotokezaka A, Huynh LP, and Mangrum AJ. Regulation of adenylyl cyclase in polarized renal epithelial cells by G protein-coupled receptors. Am J Physiol Renal Physiol 273: F883-F891, 1997.
36. Okusa MD, Linden J, Huang L, Rieger JM, Macdonald TL, and Huynh LP. A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol 279: F809-F818, 2000.
37. 2A-adenosine receptor activation and PDE 4 inhibition. Kidney Int 59: 2114-2125, 2001.
38. Okusa MD, Linden J, Macdonald T, and Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol Renal Physiol 277: F404-F412, 1999.
39. Olah ME and Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35: 581-606, 1995.
40. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, and Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997.
41. Parving HH, Osterby R, and Ritz E. Diabetic nephropathy. In: The Kidney, 6th ed., edited by Brenner BM. Philadelphia, PA: WB Saunders, 2000, p. 1731-1773.
42. Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, and van Es LA. Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48: 1477-1486, 1995.
43. Raats CJ, van den BJ, Bakker MA, Oppers-Walgreen B, Pisa BJ, Dijkman HB, Assmann KJ, and Berden JH. Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 156: 1749-1765, 2000.
44. Rieger JM, Brown ML, Sullivan GW, Linden J, and Macdonald TL. Design, synthesis, and evaluation of novel A2A adenosine receptor agonists. J Med Chem 44: 531-539, 2001.
45. Rovin BH, Yoshiumura T, and Tan L. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunol 148: 2148-2153, 1992.
46. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, and Freeman BA. Tumor necrosis factor and interleukin 1α increase vascular endothelial permeability. Am J Physiol Lung Cell Mol Physiol 257: L399-L410, 1989.
47. Schwarz K, Simons M, Reiser J, Saleem MA, Faul C, Kriz W, Shaw AS, Holzman LB, and Mundel P. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 108: 1621-1629, 2001.
48. Smoyer WE and Mundel P. Regulation of podocyte structure during the development of nephrotic syndrome. J Mol Med 76: 172-183, 1998.
49. 2A adenosine receptors in inflammation. Drug Dev Res 45: 103-112, 1998.
50. Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, and Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A2A receptor agonists. Br J Pharmacol 132: 1017-1025, 2001.
51. Tatchum-Talom R, Gopalakrishnan V, and McNeill JR. Radiotelemetric monitoring of blood pressure and mesenteric arterial bed responsiveness in rats with streptozotocin-induced diabetes. Can J Physiol Pharmacol 78: 721-728, 2000.
52. The United States Renal Data System. USRDS Annual Data Report. Bethesda, MD. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001.
53. Vitzthum H, Weiss B, Bachleitner W, Kramer BK, and Kurtz A. Gene expression of adenosine receptors along the nephron. Kidney Int 65: 1180-1190, 2004.
54. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukoida N, Naito T, Matsushima K, and Yokoyama H. Upregulation of MCP-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58: 1492-1498, 2000.
55. Wolf G and Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393-405, 1999.